Although other approaches are also able to lower eATP levels, such as the blockers of Panx-1 channel by carbenoxolone (CBX) or mimetic peptide 10panx1 [8,39,40], we believe that rAAV-CD39 vector can be an alternative treatment for asthma patients, having the advantages of stable and long-term gene expression, specific tissue tropism, and an impact on local immune responses. This evidence concerns the gene ENTPD1 and asthma.